Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Mission Should Not Include Rx Cost-Effectiveness, Rep. Allen Says

Executive Summary

FDA is not the appropriate agency to oversee comparative research involving drugs and devices, Rep. Tom Allen (D-Maine) says
Advertisement

Related Content

CMS To Issue Clinical Evidence Policy Paper In August
CMS To Issue Clinical Evidence Policy Paper In August
CMS, Industry To Debate “Practical” Trials On July 20 Audio Conference
CMS, Industry To Debate “Practical” Trials On July 20 Audio Conference
Generic Biologics Approval Process Is Focus Of Employers’ Coalition
Generic Biologics Approval Process Is Focus Of Employers’ Coalition
AHRQ Comparative Research Agenda Due June 8; HHS Priorities Will Be Key
FDA Will Be Given Cost-Effectiveness Role, Acting Commissioner Predicts
FDA Will Be Given Cost-Effectiveness Role, Acting Commissioner Predicts
Advertisement
UsernamePublicRestriction

Register

PS043858

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel